The estimated Net Worth of Ali Ph.D. Fattaey is at least 591 千$ dollars as of 15 November 2017. Ali Fattaey owns over 50,000 units of Curis Inc stock worth over 591,039$ and over the last 12 years Ali sold CRIS stock worth over 0$.
Ali has made over 3 trades of the Curis Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Ali bought 50,000 units of CRIS stock worth 53,000$ on 15 November 2017.
The largest trade Ali's ever made was buying 62,890 units of Curis Inc stock on 27 August 2014 worth over 100,624$. On average, Ali trades about 9,658 units every 120 days since 2013. As of 15 November 2017 Ali still owns at least 115,890 units of Curis Inc stock.
You can see the complete history of Ali Fattaey stock trades at the bottom of the page.
Ali's mailing address filed with the SEC is C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON, MA, 02421.
Over the last 24 years, insiders at Curis Inc have traded over 10,321,234$ worth of Curis Inc stock and bought 10,678,594 units worth 25,596,192$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Discovery Technologies Ltd ...、James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of 811,553$. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth 17,160$.
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Curis Inc executives and other stock owners filed with the SEC include: